Physician profile
Brian W Mitchell
NPI 1548212475
$5,225.19
in general payments reported to CMS, 2019-2025
51 companies · $1,278 in 2025
The $1,278 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $97.87 · 2021: $532 · 2022: $617 · 2023: $1,200 · 2024: $1,224 · 2025: $1,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.38 | 2021-2025 | |
| Ucb, INC. | $312.05 | 2021-2025 | Nayzilam, Briviact, Rystiggo |
| Novartis Pharmaceuticals Corporation | $293.71 | 2019-2025 | |
| Pfizer INC. | $249.84 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $238.51 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $208.44 | 2020-2024 | Vyepti |
| Biogen, INC. | $195.92 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Sunovion Pharmaceuticals INC. | $154.15 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $149.66 | 2021-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $148.47 | 2023-2025 | |
| Sk Life Science, INC. | $141.62 | 2021-2024 | |
| Eisai INC. | $140.36 | 2024-2025 | |
| Amgen INC. | $132.17 | 2021-2024 | Uplizna, Aimovig |
| Allergan, INC. | $108.21 | 2019-2022 | |
| Lilly USA, LLC | $100.78 | 2022-2024 | Reyvow, Emgality, Amyvid |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.